Company News

Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Behrman Capital has a 25-year track record of successfully investing in growing healthcare services companies, adding resources and professional services to help them innovate and expand.

“This is a substantial and exciting milestone in our evolution,” said Dr. Anne Lindblad, president and chief executive officer of Emmes. “The Emmes name will continue, as will our vision, mission, leadership, and focus on advancing human health. We will benefit from Behrman’s investment, expertise and relationships. We believe this investment will allow us to provide employees even greater opportunities as we continue to build and grow.

“Our government work is and will remain core, and we plan to accelerate our efforts on the non-government side,” she added.

According to Grant Behrman, managing partner of Behrman Capital, “Emmes has world class talent and an outstanding reputation in clinical research. It has built an especially strong legacy in the government sector and, in particular, at the National Institutes of Health. Our role is to invest in the company’s future growth, from employee development to expanded offerings to current and prospective clients.”

“We believe Behrman’s investment will speed the development and integration of tools that increase the efficiency of conducting research studies,” noted Dr. Lindblad. “This should have a direct, positive impact to our clients. In addition, Behrman will be a great help in expanding our global presence, sharing market research that can shape new business opportunities, and identifying key hires that would complement our existing team.”

Last year, Emmes was 83rd, up from 95th the previous year, in the Washington Business Journal’s annual ranking of the area’s top private companies. It also was one of only two biotech companies recognized by The Washington Post in its Top Workplaces ranking. The company’s revenues have increased nearly 27% percent over the past two years, from $90 million in 2016 to $114 million in 2018. The company has two offices in Maryland, one in Northern Virginia, one in Canada, and two in India.

About Behrman Capital
Based in New York City and San Francisco, Behrman Capital was founded in 1991 by Grant G. and Darryl G. Behrman. It has raised more than $3 billion since its formation, and healthcare services is one of the firm’s three industry focuses.

About Emmes
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.

Company News

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced significant progress in its role as Data Coordinating Center for studies conducted under the Best Pharmaceuticals for Children Act (BPCA).

Results from the Emmes-managed clinical trials, conducted through the BPCA Clinical Coordinating Center at Pediatric Trials Network, contributed directly to improved drug labeling for a range of products used in treating infants and children. The four newest label changes related to caffeine citrate, used to treat apnea of prematurity, plus three antibiotics: doxycycline, clindamycin, and trimethoprim-sulfamethoxazole (often referred to by its trade name Bactrim™). With the revised labeling for Ampicillin, announced early last year, there were a total of five Emmes-supported label changes during 2020.

According to Ravinder Anand, Ph.D., Emmes’ Vice President of Maternal Child Health, “These are the most approvals ever gained in a single year under the BPCA program. We are proud of our role in these accomplishments for our client, the National Institute of Child Health and Human Development (NICHD).”

He added, “The improvements associated with these label changes provided weight base dosing recommendations for clindamycin; information on pediatric pharmacokinetics for doxycycline and Bactrim; and a broader treatment-eligible age range and extended treatment duration when using caffeine to treat premature infants with apnea of prematurity.”

Under the NICHD contract, Emmes provides end-to-end clinical study support and management, which includes data management, regulatory support, pharmacovigilance, site monitoring, and statistical analyses for the studies. The company has served as the Data Coordinating Center for the BPCA program since August 2009 and has supported 11 labeling and two other marketing approvals from the U.S. Food and Drug Administration (FDA). These changes have addressed either pharmacokinetics, dosage, safety and/or efficacy information for a variety of pediatric drugs and devices across various pediatric populations and treatment indications.

Emmes’ Chief Executive Officer, Dr. Christine Dingivan, said, “These drug labeling approvals reinforce our commitment to excellence in study design, execution and analysis. This is an important public sector program and a valued client. Emmes has a long history of pediatric clinical research, and our team is so proud of our role in improving public health outcomes and safe, effective drug development in children.”

About the Research
The BPCA program is funded by the National Institutes of Health through its Eunice Kennedy Shriver National Institute of Child Health and Human Development. This program supports the Pediatric Trials Network, which studies commonly prescribed off-patent drugs whose original development did not include pediatric patients. Study results are intended to amend FDA-approved prescribing information. This project has been funded in whole or in part with Federal funds from the National Institutes of Health under Contract No. HHSN275201700002C.

About Emmes
Founded in 1977, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.

Company News

Transaction Expands Emmes’ Biopharma Effort and European Presence

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Neox s.r.o., a European-based CRO. Neox will add over 150 employees who support biotechnology, pharmaceutical, and medical device companies.

“This is an important and exciting step for Emmes, demonstrating significant progress on our strategic plans to grow our biopharmaceutical business,” said Dr. Christine Dingivan, Chief Executive Officer of Emmes. “Neox adds a sizable, well-established biopharmaceutical research services business to Emmes and significantly expands our international presence.”

Based in Prague, Neox has operations primarily in central and eastern Europe, with a direct presence in the Czech Republic, Bulgaria, Germany, Hungary, Poland, Romania, Slovakia and Slovenia. The company operates in another 11 European countries, including a recently established entity in the United Kingdom. Founded in 2004 by brothers Dr. Pavel Marek and Petr Marek, Neox has provided clinical research support for more than 1,000 studies and has built deep experience across multiple therapeutic areas. Both Pavel and Petr Marek will remain with Neox and continue to serve in their leadership roles. “Pavel and his team have built a CRO with an excellent reputation,” noted Dr. Dingivan. “Our companies share a dedication to science, long-term partnerships with clients, and a corporate culture that centers on integrity, agility and passion for excellence.”

According to Dr. Marek, “Neox and Emmes will be a powerful combination. We look forward to continuing to serve our customers with the expanded resources of the Emmes organization, as well as helping Emmes support rapid patient enrollment in global clinical trials. Our regulatory contacts throughout Europe, who understand country-specific requirements, will be an asset in helping Emmes’ current and future biopharma customers with their global drug development strategic planning and clinical operations.”

Emmes conducts its operations from, and is focused on growing, its two strategic business groups: Emmes Biopharma and Emmes Public Sector. Neox will be part of Emmes Biopharma, which also includes Emmes’ established, experienced teams in the USA, India and Canada.

“Neox will broaden our biopharmaceutical platform by expanding our customer base and capabilities to conduct global trials at sites across the US, Canada, UK, EU, and India,” noted Dr. Dingivan. “The acquisition will leverage the systems and technology investments Emmes has made to support future growth.”

This acquisition will bring the total number of employees at Emmes to over 1,000 across the globe.

About Emmes Founded in 1977, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.

Company News

Emmes reported revenues of $125 million in 2019 and has more than 750 employees globally. More than 675 employees work in Maryland, Virginia and Washington, D.C.

The company is expecting to hire nearly 70 new employees to support new and expanded clinical research projects. This represents an increase of approximately 10 percent of its area-wide workforce. The positions include clinical operations staff, biostatisticians, bioinformatics experts, project control analysts, project managers, data management staff, technical writers, clinical research auditors, and proposal manager. The company has offices in Rockville, MD, Frederick, MD and Tysons Corner, VA. Emmes continues to maintain a robust teleworking environment.

“We provide the backbone of support to both government and biopharmaceutical companies involved in developing treatments and vaccines associated with a wide range of diseases and disorders,” said Dr. Anne Lindblad, president and chief executive officer. “Our operational, data management, regulatory, safety, statistical and data analysis support for clinical trials and human health research is highly valued, and the result is continued growth. This means promoting employees, giving people more opportunities for job expansion and flexibility, and adding new staff.”

Dr. Lindblad noted that three new executives have joined the leadership team since November: a chief business officer, vice president of clinical operations, and chief medical officer. Two new business development directors were just hired. The company also promoted three employees to the position of vice president.

About Emmes
Emmes is a leading Contract Research Organization working with both public and private sector organizations. We collaborate with our clients to produce valued, trusted scientific research, and our team members are passionate about making a difference in the quality of human health. Emmes has supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.